Cumberland Pharmaceuticals Hits New 52-Week High of $9.20

Cumberland Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 9.20 on August 26, 2026. This achievement marks a remarkable increase of 531.69% over the past year, significantly outperforming the S&P 500, which has seen a gain of 18.71% during the same period. As a microcap company in the Pharmaceuticals & Biotechnology sector, Cumberland Pharmaceuticals has a market capitalization of USD 46 million. Despite its recent price surge, the company remains in a loss-making position, with a negative return on equity of -11.00%. The stock's price-to-book ratio stands at 1.85, indicating its valuation relative to its net assets. Cumberland's debt-to-equity ratio is reported at -0.23, reflecting a unique financial structure. The company does not offer a dividend yield, aligning with its focus on growth within the competitive pharmaceutical landscape. The stock's previous 52-week low was recorded at USD 1.85, highlighting the significant upward movement in its price.